Relistor panel set for March

Salix Pharmaceuticals Inc. (NASDAQ:SLXP) said FDA will convene an advisory committee meeting on March 10-11, 2014, to discuss the biotech's appeal of a July 2012 complete response letter for subcutaneous Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in patients with chronic pain. According to Salix, FDA said it will take action under the appeal within 30 days after receiving input from the meeting. Relistor is approved in 58 countries, including the U.S., to treat OIC in patients receiving palliative care when response to laxative therapy has not been sufficient (see BioCentury Extra, June 11). ...